Table 7.6h Persistency of Discharge Regimen by Follow-up Period, 2006 to 2010 Recipients with Pancreas After Kidney (PAK) Transplants Year of Transplant Discharge Regimen (w/ or w/o Steroid Use) CyA+Aza At Discharge (N) At Discharge (%) 6 Months PostTx (%) 1 Year PostTx (%) 2 Years PostTx (%) 3 Years PostTx (%) CyA+MMF At Discharge (N) At Discharge (%) 6 Months PostTx (%) 1 Year PostTx (%) 2 Years PostTx (%) 3 Years PostTx (%) CyA+Siro At Discharge (N) At Discharge (%) 6 Months PostTx (%) 1 Year PostTx (%) 2 Years PostTx (%) 3 Years PostTx (%) Siro+MMF At Discharge (N) At Discharge (%) 6 Months PostTx (%) 100.0% 100.0% 100.0% 1 Year PostTx (%) 2 Years PostTx (%) 3 Years PostTx (%) At Discharge (N) At Discharge (%) 6 Months PostTx (%) 1 Year PostTx (%) 2 Years PostTx (%) 3 Years PostTx (%) (Continued)
Source: OPTN/SRTR Data as of December 4, 2012. Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen(CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimenchange. Rates are calculated for the most common discharge regimens. CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus. See Technical Notes for further details. Table 7.6h Persistency of Discharge Regimen by Follow-up Period, 2006 to 2010 Recipients with Pancreas After Kidney (PAK) Transplants Year of Transplant Discharge Regimen (w/ or w/o Steroid Use) Tac+MMF At Discharge (N) At Discharge (%) 6 Months PostTx (%) 1 Year PostTx (%) 2 Years PostTx (%) 3 Years PostTx (%) Tac+Siro At Discharge (N) At Discharge (%) 6 Months PostTx (%) 1 Year PostTx (%) 2 Years PostTx (%) 3 Years PostTx (%)
Source: OPTN/SRTR Data as of December 4, 2012. Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen(CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimenchange. Rates are calculated for the most common discharge regimens. CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus. See Technical Notes for further details.
New Scientist and Greenpeace Science Debates Science, technology and our future: the big questions Technology: taking the good without the bad 14th May 2002 Brian Aldiss, Writer Brian Aldiss: I’m going to try and be a little more cheerful than Ian was, although it’s true that not all technical advances are advantageous. We all know that feeding fooddesigned for carnivores
Substance Abuse Treatment Breaking News for the T reatment Field Acamprosate: A New Medication for Alcohol Use Disorders What is acamprosate? glutamate and gamma-aminobutyric acid (GABA) neurotransmitter systems. Although acamprosate’s Acamprosate (calcium acetyl homotaurinate) is a mechanism of action has not been clearly established, new prescription medication t